Breakthrough Weight Loss Jab: Tirzepatide Shows Big Results

Shutterstock.com

A once-weekly injection hailed as the “King Kong” of weight loss jabs, Tirzepatide showed promise in helping people shed nearly a fifth of their body weight.

Last month, the National Institute for Health and Care Excellence recommended Tirzepatide for people with type 2 diabetes intolerant to metformin. However, its appetite-suppressing properties position it as a potent tool in the fight against obesity, surpassing other drugs such as semaglutide.

A recent study, led by Professor Thomas Wadden from the University of Pennsylvania and published in the journal Nature Medicine, focused on 287 participants who had successfully lost at least 5% of their weight through diet and exercise.

Individuals in this category often regain about a third of their lost weight. However, those who received Tirzepatide saw an additional average reduction of 18.4% in body weight over the course of a year.

Professor Wadden said that “Slimmers often hit a wall, where they cannot get beyond losing five to 10 per cent of their weight – but this drug could help them achieve substantially more.”

The drug provided benefits beyond weight loss, including reductions in blood pressure and cholesterol levels, as well as improved blood sugar control.

The pharmaceutical giant Eli Lilly, the manufacturer of Tirzepatide, funded the trial. In the fight against excess weight, Tirzepatide is emerging as a promising contender and offers hope for those struggling with conventional weight loss strategies.

Nonetheless, the study acknowledges the potential side effects of nausea, diarrhea, and constipation, which were mitigated by gradually introducing the Tirzepatide dose over four months. Weight loss jab critics warn about potential long-term risks, saying more research is needed into their safety and effectiveness.